|
Gene: HSD17B14 |
Gene summary for HSD17B14 |
Gene summary. |
Gene information | Species | Human | Gene symbol | HSD17B14 | Gene ID | 51171 |
Gene name | hydroxysteroid 17-beta dehydrogenase 14 | |
Gene Alias | DHRS10 | |
Cytomap | 19q13.33 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | A0A140VJH8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51171 | HSD17B14 | HCC1_Meng | Human | Liver | HCC | 1.78e-40 | 1.22e-01 | 0.0246 |
51171 | HSD17B14 | HCC2 | Human | Liver | HCC | 1.85e-25 | 4.30e+00 | 0.5341 |
51171 | HSD17B14 | S014 | Human | Liver | HCC | 4.16e-06 | 3.08e-01 | 0.2254 |
51171 | HSD17B14 | S015 | Human | Liver | HCC | 1.16e-13 | 5.93e-01 | 0.2375 |
51171 | HSD17B14 | S016 | Human | Liver | HCC | 1.68e-02 | 2.43e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
GO:001604221 | Liver | HCC | lipid catabolic process | 175/7958 | 320/18723 | 6.50e-06 | 7.88e-05 | 175 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSD17B14 | SNV | Missense_Mutation | novel | c.308N>G | p.Ser103Cys | p.S103C | Q9BPX1 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
HSD17B14 | SNV | Missense_Mutation | c.797C>G | p.Pro266Arg | p.P266R | Q9BPX1 | protein_coding | deleterious_low_confidence(0.01) | benign(0.149) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
HSD17B14 | SNV | Missense_Mutation | rs748792003 | c.8C>T | p.Thr3Met | p.T3M | Q9BPX1 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HSD17B14 | SNV | Missense_Mutation | c.300N>T | p.Glu100Asp | p.E100D | Q9BPX1 | protein_coding | tolerated(0.84) | benign(0.003) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HSD17B14 | SNV | Missense_Mutation | c.323N>A | p.Arg108His | p.R108H | Q9BPX1 | protein_coding | deleterious(0.04) | benign(0.187) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HSD17B14 | SNV | Missense_Mutation | novel | c.700G>A | p.Glu234Lys | p.E234K | Q9BPX1 | protein_coding | deleterious(0.01) | possibly_damaging(0.795) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
HSD17B14 | SNV | Missense_Mutation | rs755171561 | c.353N>T | p.Thr118Met | p.T118M | Q9BPX1 | protein_coding | tolerated(0.19) | benign(0.074) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
HSD17B14 | insertion | Frame_Shift_Ins | novel | c.281_282insC | p.Pro95ThrfsTer6 | p.P95Tfs*6 | Q9BPX1 | protein_coding | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
HSD17B14 | SNV | Missense_Mutation | rs201026226 | c.236G>A | p.Arg79Gln | p.R79Q | Q9BPX1 | protein_coding | tolerated(0.41) | benign(0.009) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HSD17B14 | SNV | Missense_Mutation | novel | c.425N>C | p.Leu142Pro | p.L142P | Q9BPX1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |